Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Alpha-GPC and Physical and Cognitive Performances in Volleyball Players. (VolleyAGPC)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Université de Montréal
Sponsor:
Information provided by (Responsible Party):
Raynald Bergeron, Université de Montréal
ClinicalTrials.gov Identifier:
NCT02886130
First received: August 24, 2016
Last updated: August 26, 2016
Last verified: August 2016
  Purpose

In order to attain the elite level on the national scene, volleyball players need several attributes. In addition to mastering technical and tactical skills, great jumping ability is another important asset. Maximal power output needed to achieve height during a jump necessitates coordinated neuromuscular recruitment and muscle mass among others. Interestingly, there are claims that alpha-glycerylphosphorylcholine (A-GPC) increases acetylcholine synthesis and enhances exercise-induced increases in plasma growth hormone concentrations, two factors that could theoretically be associated neuromuscular transmission and muscle mass.

However, until now only a few studies have investigated the role of A-GPC in human exercise performance. Published results were mixed. One recent study showed that isometric peak force was slightly but significantly increased when subjects had ingested a daily dose of 600 mg of A-GPC over a period of 6 days (Bellar et al., JISSN, 2015).

The objective of our study is to evaluate the longer-term effects (4 weeks) using a higher dose (1000 mg/day) of A-GPC on jumping capabilities in elite male and female volleyball players.


Condition Intervention Phase
Athletic Performance
Dietary Supplement: Placebo
Dietary Supplement: Experimental
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Basic Science
Official Title: Effects of Alpha-glycerylphosphorylcholine on Physical and Cognitive Performances in Varsity Volleyball Players

Further study details as provided by Université de Montréal:

Primary Outcome Measures:
  • Change in countermovement jump performance at 4 weeks [ Time Frame: Assessments at week 0 and at week 4 of supplementation or placebo ] [ Designated as safety issue: No ]
    Jump height is calculated using two forces plates which measures the time the feet are off the platform. The athlete stands upright with weight evenly distributed over both feet. Hands are placed on the hips, and stay there throughout the test. When all is ready, the athlete squats down until the knees are bent at 90 degrees, then immediately jumps vertically as high as possible, landing back on the platform on both feet at the same time. Allow a good rest between trials. The take-off must be from both feet, with no initial steps or shuffling. They must also not pause at the base of the squat.


Secondary Outcome Measures:
  • Change in vertical jump - run up at 4 weeks [ Time Frame: Assessments at week 0 and at week 4 of supplementation or placebo ] [ Designated as safety issue: No ]
    Record the standing height of the subject by getting then to stand directly below the apparatus with both feet on tip-toes, and then stretch up one arm and reach as high as possible. The subject then stands the appropriate distance from the base of the apparatus (about 15 feet), and when ready take 3 or so steps before leaping off up off both legs as high as possible, using the arms to assist in projecting the body upwards. The subject should aim to take off just short of the apparatus, so that at the peak of the jump they are directly under it.

  • Executive function [ Time Frame: After 4 weeks of supplementation or placebo ] [ Designated as safety issue: No ]
    "Task switching" is a useful tool to investigate executive functions in humans. This task allows investigation of the ability to maintain, select and switch among task sets.


Estimated Enrollment: 28
Study Start Date: August 2016
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
Dietary Supplement: Placebo
Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Other Names:
  • Maltodextrin
  • Control
Experimental: Alpha-GPC
Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration
Dietary Supplement: Experimental
Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Other Names:
  • Alpha-gpc
  • Alpha-glycerylphosphorylcholine
  • Alpha-gpc supplementation
  • A-GPC

Detailed Description:
Our study design will be a placebo controlled, randomized, double-blind, crossover study. Varsity male and female volleyball players (n=28) will each be asked to participate in both arms of the study, i.e. placebo and A-GPC (1000 mg/kg/day). The duration of each arm of the study will be 4 weeks separated by a 7-day washout period. The order of treatment (placebo or A-GPC) will be determined randomly. Athletes will be asked to maintain their training load during the duration of the experiment.
  Eligibility

Ages Eligible for Study:   19 Years to 30 Years   (Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be a competitive varsity volleyball player

Exclusion Criteria:

  • Regular consumption of alpha-GPC within the last 4 months
  • Receiving drug treatment except 1) contraception (pill), and 2) treatment against asthma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02886130

Contacts
Contact: Samuel St-Arnaud, B.Sc 819-696-7889 sam.st-arnaud@hotmail.com
Contact: Raynald Bergeron, Ph.D 514-343-6823 raynald.bergeron@umontreal.ca

Locations
Canada, Quebec
CEPSUM (Centre d'éducation physique et des sports de l'université de Montréal) Recruiting
Montreal, Quebec, Canada, H3C3J7
Contact: Samuel St-Arnaud, BSc    819-696-7889    samuel.st-arnaud@umontreal.ca   
Contact: Raynald Bergeron, PhD    514-343-6823    raynald.bergeron@umontreal.ca   
Sponsors and Collaborators
Université de Montréal
Investigators
Principal Investigator: Samuel St-Arnaud, B.Sc Université de Montréal
Study Director: Raynald Bergeron, Ph.D Université de Montréal
Study Director: Jonathan Tremblay, Ph.D Université de Montréal
  More Information

Additional Information:
Publications:

Responsible Party: Raynald Bergeron, Associate professor, Université de Montréal
ClinicalTrials.gov Identifier: NCT02886130     History of Changes
Other Study ID Numbers: Montreal 
Study First Received: August 24, 2016
Last Updated: August 26, 2016
Health Authority: Canada: Health Canada
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: Individual data obtained from vertical jump assessments and during the cognitive switch task will be communicated to each athlete.

Keywords provided by Université de Montréal:
Alpha-GPC
Volleyball
Athletes
Executive functions
Vertical jump
Peak power

ClinicalTrials.gov processed this record on January 17, 2017